Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by American Century Companies Inc.

American Century Companies Inc. lessened its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 4.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 250,861 shares of the biopharmaceutical company’s stock after selling 11,923 shares during the period. American Century Companies Inc. owned approximately 0.19% of Dynavax Technologies worth $2,817,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of DVAX. Duality Advisers LP acquired a new position in Dynavax Technologies during the 1st quarter worth about $227,000. Boston Partners acquired a new position in Dynavax Technologies during the 1st quarter worth about $292,000. China Universal Asset Management Co. Ltd. lifted its stake in Dynavax Technologies by 67.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,099 shares of the biopharmaceutical company’s stock worth $311,000 after acquiring an additional 10,143 shares in the last quarter. Choreo LLC acquired a new position in Dynavax Technologies during the 2nd quarter worth about $363,000. Finally, Diversified Trust Co lifted its stake in Dynavax Technologies by 3.2% during the 1st quarter. Diversified Trust Co now owns 29,548 shares of the biopharmaceutical company’s stock worth $367,000 after acquiring an additional 925 shares in the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on DVAX shares. HC Wainwright reissued a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a research note on Wednesday, August 7th. The Goldman Sachs Group reduced their price target on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $23.67.

Dynavax Technologies Price Performance

DVAX stock opened at $11.00 on Friday. The company has a debt-to-equity ratio of 0.35, a current ratio of 14.18 and a quick ratio of 13.18. The firm has a market capitalization of $1.44 billion, a P/E ratio of 183.17 and a beta of 1.37. The business’s 50-day moving average is $11.07 and its two-hundred day moving average is $11.43. Dynavax Technologies Co. has a 1 year low of $9.74 and a 1 year high of $15.15.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. The company had revenue of $73.80 million for the quarter, compared to analyst estimates of $76.92 million. During the same quarter last year, the company earned $0.03 EPS. Analysts anticipate that Dynavax Technologies Co. will post 0.16 earnings per share for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.